4/10 · Low-Moderate — near-term order acceleration is real (orders +56% YoY), but a $54B cap in a cyclical test-and-measure niche and fading FY29 estimates cap the multibagger
Technicals
Mixed — $314, −15.9% off 52-wk high, below 50-DMA ($347) but above 200-DMA ($254), RSI 42, +91% 12-mo (SPY +21%)
Cyclical demand reversal — the order book that is inflating today can deflate fast, and 52× leaves no cushion
One-line thesis. Keysight is a genuinely high-quality, wide-moat electronic test-and-measurement franchise firing on all cylinders right now (record H1 FY26, orders topping $2B/quarter, full-year outlook raised) — but after a ~90% twelve-month run the stock trades at 52× trailing / 31× forward earnings for a business whose demand is structurally cyclical, so we rate it Watch: own the business, wait for a better price.
◆ Synthos call — HoldKEYS is a solid business largely reflected at ~$300 — fine to keep, no reason to chase; it gets interesting again below ~$255.
Downside Risk (lower = safer)
6/10 · High
Fortress balance sheet (net-debt/EBITDA 0.24×) but 52× trailing, beta 1.22, cyclical order book, -6.5% one-day drop.
Real acceleration in the near term (orders +56% YoY), but a $54B cap in a cyclical T&M niche caps the multibagger; estimates fade after FY28.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 26%/yrTo justify today’s $314, earnings would have to compound roughly 26% a year for 10 years (9% discount rate). Analysts forecast ~6%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Keysight makes the expensive test-and-measurement gear that engineers use to design and check electronics — oscilloscopes, signal analyzers, network and chip testers, plus the software around them. If a company is building a 5G radio, a self-driving-car sensor, an AI data-center switch, or a new semiconductor, there's a good chance a Keysight machine verified it works. It's the "picks-and-shovels" supplier to the whole electronics industry.
The business is doing very well right now: this was the strongest first half in company history, and orders are coming in faster than the company can ship them. The catch is the price. After the stock nearly doubled in a year, you're paying about 52 dollars for every 1 dollar of last year's profit — a very rich price for a company whose sales rise and fall with the electronics-spending cycle. When that cycle turns down (and it always eventually does), a stock priced this high can fall hard. That's why our verdict is Watch — a good company, but wait for a cheaper entry.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit riskier than average). The company itself is financially very safe (almost no net debt), but the stock is expensive and swings more than the market, and it just dropped 6.5% in a single day.
Growth Quality 7/10 (good). Solid, profitable growth with a real competitive moat — but tied to a boom-and-bust industry.
Exponential Potential 4/10 (limited). It can keep growing, but at $54 billion in a specialized niche, don't expect it to multiply several times over.
The one big worry: Keysight's business is cyclical. Today's booming order book is the good part of the cycle. If electronics and semiconductor spending cools, orders and the stock could both drop quickly — and there's no bargain-price cushion to soften the fall.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLK (sector)), set to 100 a year ago
Solid = KEYS · dashed = S&P 500 · dotted = XLK (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$313.86
Market cap$54B
P/E trailing14×
P/E FY26E / FY27E31× / 27×
EV / Sales8.9×
EV / EBITDA37.5×
Gross margin63.7%
Net margin17.2%
Dividend yield0.00%
Beta1.221
52-wk range$159 – $373
RSI(14)42
50 / 200-DMA$347 / $254
12-mo return+91% (SPY +21%)
Street target$390 ($350–$425)
Analyst grades12 Buy · 4 Hold · 0 Sell
FMP ratingB-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on KEYS · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Keysight Technologies (NYSE: KEYS) is the world's leading pure-play electronic design, emulation, and test-and-measurement company. Spun out of Agilent in 2014 (and originally the Hewlett-Packard test-and-measurement business founded in 1939), it sells the precision instruments and software used to design and validate electronics across communications, aerospace/defense, automotive/energy, semiconductor, and general electronics. Fiscal year ends October 31.
Two reporting segments (FY2024, latest full-year segmentation in the data):
Communications Solutions Group (CSG) — $3.42B (69% of revenue): RF/microwave test, network test, EDA software, wireless/5G/6G, data-center and aerospace-defense test. This is the higher-growth engine; in Q2 FY26 CSG grew +35% YoY, led by +40% commercial communications and +24% aerospace/defense/government.
Electronic Industrial Solutions Group (EISG) — $1.56B (31%): general-purpose lab and industrial instruments (multimeters, function generators, source-measure units), automotive/energy test, semiconductor parametric test, and board-assembly test. Q2 FY26 EISG grew +24% YoY with double-digit growth across all end markets.
Geographic revenue (FY2024): Americas $2.06B · Asia Pacific $1.99B · Europe $0.93B. Roughly balanced between the Americas and Asia — meaning meaningful exposure to Asian semiconductor/electronics capex and to US export-control and tariff policy (the Q2 filing details a $100M IEEPA tariff-refund receivable following a February 2026 Supreme Court ruling).
The strategic frame: Keysight is a software-and-services-enriched instrument company riding the secular complexity of 5G→6G, AI data-center networking, automotive electrification, and advanced-node semiconductors — but selling capital equipment whose order flow is inherently cyclical.
2. The expert thesis — why the panel is bullish (traceable)
There is no expert thesis to report. Keysight has zero coverage in the Synthos knowledge base — total_claims: 0, net_bullish_voices: 0, and an empty top array. No distilled voice, bullish or cautionary, has been ingested for this name.
What that means for this note (stated plainly): this verdict carries no conviction-track weight. It is built entirely from (a) reported FMP fundamentals, (b) live analyst consensus estimates, and (c) our own quant/valuation model. Nothing below cites a claim_id because there are none to cite — and per house standard we will never fabricate one. A reader should treat this as a rigorous fundamentals-and-quant read, not an expert-panel-corroborated conviction call. The absence of coverage is itself a reason the verdict lands at Watch rather than Buy.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Moderate-High
Balance sheet is a fortress (net-debt/EBITDA 0.24×, current ratio 1.9×, interest coverage 10×) — but 52× trailing / 31× forward, beta 1.22, a cyclical order book near a cycle peak, and a −6.5% single-day drop all argue the stock (not the company) carries real drawdown risk.
Growth Quality
7 · Good
~15% forward revenue CAGR and ~20% forward EPS CAGR, 63.7% gross margin, ROE 17.4%, ROIC 10.2%, a wide T&M moat and sticky software attach — dinged because demand is structurally cyclical, not secular-compounding.
Exponential Potential
4 · Low-Moderate
Near-term acceleration is real (orders +56% YoY in Q2, full-year raised), but a $54B cap in a specialized cyclical niche and estimates that fade after FY28 cap the multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
The upcycle runs: CSG stays +30%+, AI-networking and 6G test demand compounds, EISG re-accelerates. FY27E EPS beats to ~$13 (vs $11.80 cons); the market keeps paying a peak-cycle ~31×.
~$405 (+29%)
Base(our anchor)
Estimates roughly hit — FY27E EPS ~$11.80; a good-but-cyclical compounder de-rates modestly toward a ~25× through-cycle multiple.
~$300 (−4%)
Bear
The order book rolls over (it is cyclical); FY27E EPS misses to ~$10.5 and the multiple compresses to a recession ~20× as the market front-runs the downturn.
~$210 (−33%)
Synthos fair value = the base case, ~$300 (−4%), with the full $210–$405 span as the honest range. Our base sits below the Street's $390 consensus because we (a) refuse to capitalize peak-cycle earnings at a peak-cycle multiple and (b) give zero conviction credit in the absence of any expert corroboration. Our bull ($405) roughly meets the Street high ($425); our bear ($210) is well below the Street low ($350) because the Street models are not underwriting a cyclical reversal. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). KEYS is a quality cyclical compounder with a genuine — but likely temporary — burst of acceleration:
Forward growth: revenue CAGR FY25→FY28E ~15.3% ($5.38B → $8.24B); EPS (non-GAAP) CAGR ~20%+ as margins and buybacks lift the bottom line.
Acceleration (the 2nd derivative) is positive right now but not durable: revenue growth is re-accelerating off the FY25 trough (FY25 +8% → FY26E +28% → FY27E +11% → FY28E +8%), and orders grew +56% YoY in Q2 FY26 ($2.05B) — a real inflection. But this is a cyclical upswing, not a secular one: consensus revenue and EPS fade back to high-single-digit growth by FY28 and estimates actually dip in FY29 ($11.18 EPS avg, on just 1 analyst). The acceleration is the good half of a cycle, not a new plateau.
Room to run: the served T&M / EDA market is large but specialized; at $54B the law of large numbers plus a mature, oligopolistic niche caps the multibagger. A 3× from here implies a ~$160B T&M company — larger than the entire addressable niche can plausibly support at these multiples.
Reinvestment runway: modest, high-return — capex is only ~2.4% of operating cash flow, R&D is ~19% of revenue, and the M&A engine (the $2B+ FY25 acquisition spend that lifted goodwill from $2.4B to $3.4B) is the main growth-supplement. Efficient, but not a hyperscale reinvestment story.
Exponential Potential: Low-Moderate (4/10). Own it for durable double-digit cyclical compounding, not for a fast multibagger — and be honest that today's acceleration is the flattering part of a cycle.
Revenue: FY25 (ended Oct 2025) $5.375B, +8.0% (FY24 $4.979B, which was −8.9% off FY23's $5.464B — a real cyclical dip and recovery). The business is clearly cyclical, not a straight-line compounder.
Quarterly trajectory (the acceleration): Q1'25 $1.30B → Q2 $1.31B → Q3 $1.35B → Q4 $1.42B → Q1'26 $1.60B → Q2'26 $1.72B (+31.5% YoY). Orders hit $2.05B in Q2 FY26, +56% YoY — the leading indicator is inflecting hard.
Margins: gross 63.7% TTM, EBITDA margin 23.7% TTM, operating ~18–20%, net 17.2% TTM. Software/services mix supports a structurally high gross margin for a hardware company.
Earnings: FY25 GAAP net income $846M, GAAP EPS $4.90 (diluted $4.88). Note FY25 was depressed by acquisition/amortization; non-GAAP is materially higher — Q2 FY26 non-GAAP EPS was $2.87 vs $2.02 GAAP, and the forward estimates ($10–$13) are non-GAAP. Always mind the GAAP-vs-non-GAAP gap here.
Cash flow: FY25 operating CF $1.41B, capex only −$128M, FCF $1.28B (FCF yield ~2.4% at this price). H1 FY26 free cash flow hit an all-time high per management.
Balance sheet: total debt $2.97B, cash $1.87B, net debt just $1.10B → net-debt/EBITDA 0.24×. Interest coverage 10×. Financially about as sturdy as it gets. No dividend; capital return is via buybacks (~$377M repurchased FY25).
6. Valuation — priced in or room?
There is no way to call KEYS cheap: 52× trailing GAAP EPS, 8.9× sales, 37× EV/EBITDA, 8.6× book. FMP's own letter rating is B− with a price-to-earnings sub-score of 1/5 and price-to-book 1/5 — the model flags valuation as the weak link. The bull's defense is that non-GAAP EPS grows fast: forward P/E is ~31× (FY26E) → 27× (FY27E) → 24× (FY28E) — the multiple compresses as estimates climb. But two honest cautions: (1) those are non-GAAP estimates, flattering vs the 52× GAAP trailing; and (2) capitalizing peak-cycle earnings at ~30× is exactly how cyclicals become value traps at the top. A PEG of ~1.24 (trailing) rising to ~3.2 (forward) signals the easy multiple-vs-growth trade is gone. Street targets (context): consensus $390, high $425, low $350 — notably, even the Street low is above today's $314, i.e. the sell side sees the recent −6.5% drop as an entry, not a warning. We are more cautious: our ~$300 base FV is below consensus because we will not underwrite peak-cycle numbers at peak-cycle multiples with zero expert corroboration. Not a value buy; a quality-cyclical-at-a-full-price name to watch.
7. Technicals (from the tech block)
Trend:mixed / cooling. $313.86 sits below the 50-DMA ($346.6) but comfortably above the 200-DMA ($254.4) — the intermediate trend has rolled over even as the longer trend stays up. MACD −2.16 (negative, momentum fading).
Location:−15.9% off the 52-week high ($373.34), but +98% off the 52-week low ($158.51) — a huge 12-month run now in a pullback. Max drawdown from peak −15.9%.
Momentum: RSI(14) 42 — neutral-to-soft, neither oversold nor overbought; the −6.5% one-day drop pushed it toward the lower half of the range.
Relative strength: KEYS +90.8% 12-mo vs SPY +20.6% and QQQ +30.3% — enormous outperformance, but shorter windows are cooling (+8.3% 3-mo vs SPY +13.7% and QQQ +22.0% — now lagging both).
Read: technicals say the momentum leadership is pausing after a near-double. Below the 50-DMA with a negative MACD and a fresh −6.5% gap, there is no technical urgency to buy; a base-building period or a test toward the 200-DMA (~$254) would offer a far better risk/reward entry — which is precisely the Watch stance.
8. Moat & competitive position
Keysight's moat is real and multi-layered: (1) technology leadership and precision at the leading edge of RF/microwave, high-speed digital, and network test — where being first to support a new standard (6G, PCIe/Ethernet speeds, new node characterization) wins the design-in; (2) switching costs and installed base — labs standardize on Keysight instruments, calibration, and software, and rip-and-replace is costly; (3) software/EDA attach that raises margin and stickiness; (4) scale in R&D (~$1B/yr, ~19% of sales) that smaller rivals can't match. The category is a rational oligopoly. The honest offset: it is capital equipment tied to customer capex cycles, so the moat protects share and margin but not the cyclicality of demand.
Peer set (FMP-supplied, market cap): Teradyne $57.8B (the closest test comp — semiconductor ATE), Teledyne $30.2B, Garmin $46.3B, plus contract-manufacturing/hardware names Celestica $38.7B, Flex $50.1B, Jabil $35.8B, HPE $54.6B, Ericsson $35.7B, Sandisk, and Super Micro. The truest comparables are Teradyne (ATE) and the broader electronic-instrument group; Keysight commands a premium multiple in the set, justified only if the current growth persists through the cycle.
9. Management, capital allocation & guidance
Capital allocation: disciplined and shareholder-friendly — light capex (~2.4% of OCF), consistent buybacks (~$377M FY25), no dividend, and a bolt-on M&A engine (the ~$2B FY25 acquisition spend, which raised goodwill+intangibles to $4.7B — a watch item for future impairment if the cycle turns). Net-debt/EBITDA held at a conservative 0.24×.
Insider activity: the sampled window shows a cluster of routine executive sales at these elevated prices — CEO Satish Dhanasekaran (multiple Form 4 sales, most recent 2026-06-30 at $361), CFO Neil Dougherty, and several SVPs/directors. These read as normal 10b5-1 diversification into strength rather than a red-flag signal, but the direction (selling, not buying, near the highs) is worth noting.
Management's own guidance (half-weighted — their own book): the SEC 8-K earnings release (filed 2026-05-19, Q2 FY26) is a real earnings release and reads bullish. Management raised the full-year FY2026 outlook, citing "the strongest quarter in the company's history" and "accelerating demand." Specific dated guidance: Q3 FY26 revenue $1.730–$1.750B (midpoint ~+29% YoY) and Q3 FY26 non-GAAP EPS $2.43–$2.49 on ~173M diluted shares. This is management talking its own book at a cycle high — we half-weight it and note it corroborates the near-term acceleration but says nothing about cycle durability.
10. Catalysts & what to watch
Next earnings: 2026-08-18 (Q3'26; Street EPS $2.46, right in management's $2.43–$2.49 guide; revenue ~$1.75B). The key lines: order growth (is +56% YoY sustaining or decelerating?) and CSG commercial-communications momentum.
Order book / book-to-bill: the single most important cyclical tell — orders lead revenue by 1–3 quarters. A rollover here is the earliest warning.
AI-networking & data-center test demand: the credible secular kicker inside a cyclical business — watch CSG commercial-communications mix.
Semiconductor capex cycle: EISG semiconductor and Teradyne read-throughs signal the industrial half.
M&A integration & goodwill: the $2B+ acquisition spend must earn its return; a cycle downturn raises impairment risk on the $4.7B goodwill+intangibles.
Tariff / export policy: the IEEPA refund is a positive one-off; ongoing US-China export controls remain a swing factor for Asia revenue.
Thesis tripwires (what would change the call): two consecutive quarters of order deceleration; a book-to-bill below 1.0; a guidance cut; or non-GAAP margin compression. Conversely, a multiple de-rate toward ~25× on continued execution would flip this from Watch to Buy.
11. Key risks
Cyclicality (structural, the main risk): demand tracks customer capex in comms, semis, and industrial — the booming order book today can deflate fast, and history shows it (FY24 revenue fell ~9%). At 52× trailing there is no valuation cushion for a downturn.
Valuation / de-rating: 31× forward non-GAAP on peak-cycle earnings; any demand or margin wobble invites a sharp de-rate. FMP letter rating B− flags this.
No expert corroboration: zero Synthos KB coverage means no independent conviction check — the call rests solely on fundamentals and quant.
China / export-control & tariff exposure: significant Asia-Pacific revenue exposed to US-China policy; the IEEPA tariff situation cuts both ways.
M&A / goodwill: $4.7B goodwill+intangibles from an active acquisition strategy — impairment risk if a bought-in business underperforms through a downturn.
Insider selling into strength: a cluster of executive sales near the highs — likely routine, but not a buy signal.
12. Verdict, position sizing & monitoring
Watch. Keysight is a genuinely excellent, wide-moat, fortress-balance-sheet business (net-debt/EBITDA 0.24×, 64% gross margin, ROE 17%, FCF $1.28B) enjoying a real order-driven upcycle (orders +56% YoY, record H1, full-year raised). But three things hold us at Watch rather than Buy: (1) the stock trades at 52× trailing / 31× forward after a ~90% twelve-month run, capitalizing peak-cycle earnings at a peak-cycle multiple; (2) the business is structurally cyclical, and consensus already shows growth fading after FY28; and (3) there is zero expert coverage in the Synthos KB, so nothing corroborates a high-conviction call. Our base-case fair value (~$300) sits slightly below today's price and well below the Street's $390 — the sell side is buying the dip; we would rather wait.
Sizing: if owned at all, satellite, ≤2%, and preferably scaled in on weakness (a base-build below the 50-DMA, or a test toward the 200-DMA ~$254) rather than chased at 52×.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. A de-rate toward ~25× forward on sustained order growth would upgrade this to Buy — Tactical. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $313.86.
Single biggest risk: a cyclical demand reversal that turns today's booming order book negative — with no valuation cushion to absorb it.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — Keysight has no expert coverage in the Synthos knowledge base. This note cites no claim_ids because none exist; per house standard, conviction is never fabricated. The verdict is explicitly fundamentals- and quant-driven.
Data as-of: fundamentals 2026-04-30 (Q2 FY26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP) and are labeled as estimates; note the estimate stream is non-GAAP EPS while trailing P/E is GAAP.
Management caveat: the Q2 FY26 8-K guidance (raised FY26 outlook; Q3 rev $1.73–1.75B, EPS $2.43–2.49) is management's own book, half-weighted by design and captured at a cycle high.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").